Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.31 - $4.04 $60,089 - $73,342
-18,154 Reduced 68.79%
8,235 $27,000
Q1 2024

May 14, 2024

SELL
$3.09 - $4.56 $82,345 - $121,519
-26,649 Reduced 50.25%
26,389 $106,000
Q4 2023

Feb 13, 2024

BUY
$2.8 - $3.35 $37,581 - $44,963
13,422 Added 33.88%
53,038 $161,000
Q3 2023

Nov 13, 2023

BUY
$3.0 - $3.79 $20,487 - $25,881
6,829 Added 20.83%
39,616 $118,000
Q2 2023

Aug 14, 2023

BUY
$3.21 - $5.06 $105,246 - $165,902
32,787 New
32,787 $122,000
Q2 2022

Aug 15, 2022

BUY
$5.33 - $8.18 $111,354 - $170,896
20,892 Added 53.33%
60,067 $426,000
Q1 2022

May 09, 2022

BUY
$5.5 - $9.19 $215,462 - $360,018
39,175 New
39,175 $283,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $281M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.